-
1-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)-4-(propan-2-yl)piperazine
-
ChemBase ID:
136
-
Molecular Formular:
C26H31Cl2N5O3
-
Molecular Mass:
532.46204
-
Monoisotopic Mass:
531.18039524
-
SMILES and InChIs
SMILES:
Clc1c([C@@]2(O[C@H](CO2)COc2ccc(N3CCN(CC3)C(C)C)cc2)Cn2ncnc2)ccc(Cl)c1
Canonical SMILES:
Clc1ccc(c(c1)Cl)[C@]1(OC[C@@H](O1)COc1ccc(cc1)N1CCN(CC1)C(C)C)Cn1cncn1
InChI:
InChI=1S/C26H31Cl2N5O3/c1-19(2)31-9-11-32(12-10-31)21-4-6-22(7-5-21)34-14-23-15-35-26(36-23,16-33-18-29-17-30-33)24-8-3-20(27)13-25(24)28/h3-8,13,17-19,23H,9-12,14-16H2,1-2H3/t23-,26-/m0/s1
InChIKey:
BLSQLHNBWJLIBQ-OZXSUGGESA-N
-
Cite this record
CBID:136 http://www.chembase.cn/molecule-136.html
NAMES AND DATABASE IDS
NAMES AND DATABASE IDS
Names Database IDs
IUPAC name
|
1-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)-4-(propan-2-yl)piperazine
|
|
|
IUPAC Traditional name
|
|
Brand Name
|
Fungistat
|
Gyno-Terazol
|
Terazol
|
Terazol 3
|
Terazol 7
|
Tercospor
|
|
|
Synonyms
|
|
CAS Number
|
|
PubChem SID
|
|
PubChem CID
|
|
DATA SOURCES
DATA SOURCES
All Sources Commercial Sources Non-commercial Sources
Data Source
|
Data ID
|
Price
|
CALCULATED PROPERTIES
CALCULATED PROPERTIES
JChem
ALOGPS 2.1
H Acceptors
|
7
|
H Donor
|
0
|
LogD (pH = 5.5)
|
2.5630372
|
LogD (pH = 7.4)
|
4.3256955
|
Log P
|
5.374221
|
Molar Refractivity
|
153.1894 cm3
|
Polarizability
|
54.508034 Å3
|
Polar Surface Area
|
64.88 Å2
|
Rotatable Bonds
|
8
|
Lipinski's Rule of Five
|
false
|
Log P
|
4.58
|
LOG S
|
-4.66
|
Solubility (Water)
|
1.16e-02 g/l
|
PROPERTIES
PROPERTIES
Physical Property
Bioassay(PubChem)
Hydrophobicity(logP)
|
4.5
|
Show
data source
|
|
DETAILS
DETAILS
DrugBank
DrugBank -
DB00251
|
Item |
Information |
Drug Groups
|
approved |
Description
|
Terconazole is an anti-fungal medication, primarily used to treat vaginal fungal infections. [Wikipedia] |
Indication |
For the treatment of candidiasis (a yeast-like fungal infection) of the vulva and vagina. |
Pharmacology |
Terconazole is a triazole antifungal agent available for intravaginal use. It is structurally related to imidazole-derivative antifungal agents, although terconazole and other triazoles have 3 nitrogens in the azole ring. By inhibiting the 14-alpha-demethylase (lanosterol 14-alpha-demethylase), Terconazole inhibits ergosterol synthesis. Depletion of ergosterol in fungal membrane disrupts the structure and many functions of fungal membrane leading to inhibition of fungal growth. |
Toxicity |
The oral LD50 values were found to be 1741 and 849 mg/kg for the male and female in rat. |
Affected Organisms |
|
Biotransformation |
Systemically absorbed drug appears to be rapidly and extensively metabolized. Terconazole primarily undergoes oxidatative N- and O-dealkylation, dioxolane ring cleavage, and conjugation. |
Absorption |
Following intravaginal administration of terconazole in humans, absorption ranged from 5-8% in three hysterectomized subjects and 12-16% in two non-hysterectomized subjects with tubal ligations |
Half Life |
6.9 hours (range 4.0-11.3) |
Protein Binding |
94.9% |
Elimination |
Following oral (30 mg) administration of 14C-labelled terconazole, excretion of radioactivity was both by renal (32-56%) and fecal (47-52%) routes. |
External Links |
|
|
PATENTS
PATENTS
PubChem Patent
Google Patent